Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)

Anna Sophia McKenney; Allison N. Lau; Amritha Varshini Hanasoge Somasundara; Barbara Spitzer; Andrew M. Intlekofer; Jihae Ahn; Kaitlyn Shank; Franck T. Rapaport; Minal A. Patel; Efthymia Papalexi; Alan H. Shih; April Chiu; Elizaveta Freinkman; Esra A. Akbay; Mya Steadman; Raj Nagaraja; Katharine Yen; Julie Teruya-Feldstein; Kwok Kin Wong; Raajit Rampal; Matthew G. Vander Heiden; Craig B. Thompson; Ross L. Levine

doi:10.1172/JCI124920

Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)

Anna Sophia McKenney, Allison N. Lau, Amritha Varshini Hanasoge Somasundara, Barbara Spitzer, Andrew M. Intlekofer, Jihae Ahn, Kaitlyn Shank, Franck T. Rapaport, Minal A. Patel, Efthymia Papalexi, Alan H. Shih, April Chiu, Elizaveta Freinkman, Esra A. Akbay, Mya Steadman, Raj Nagaraja, Katharine Yen, Julie Teruya-Feldstein, Kwok Kin Wong, Raajit RampalMatthew G. Vander Heiden, Craig B. Thompson, Ross L. Levine

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Abstract

Craig B. Thompson's conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below. CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.

Original language	English (US)
Pages (from-to)	4743
Number of pages	1
Journal	Journal of Clinical Investigation
Volume	128
Issue number	10
DOIs	https://doi.org/10.1172/JCI124920
State	Published - Oct 1 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1172/JCI124920

Cite this

McKenney, A. S., Lau, A. N., Somasundara, A. V. H., Spitzer, B., Intlekofer, A. M., Ahn, J., Shank, K., Rapaport, F. T., Patel, M. A., Papalexi, E., Shih, A. H., Chiu, A., Freinkman, E., Akbay, E. A., Steadman, M., Nagaraja, R., Yen, K., Teruya-Feldstein, J., Wong, K. K., ... Levine, R. L. (2018). Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516). Journal of Clinical Investigation, 128(10), 4743. https://doi.org/10.1172/JCI124920

Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516). / McKenney, Anna Sophia; Lau, Allison N.; Somasundara, Amritha Varshini Hanasoge et al.
In: Journal of Clinical Investigation, Vol. 128, No. 10, 01.10.2018, p. 4743.

Research output: Contribution to journal › Comment/debate › peer-review

McKenney, AS, Lau, AN, Somasundara, AVH, Spitzer, B, Intlekofer, AM, Ahn, J, Shank, K, Rapaport, FT, Patel, MA, Papalexi, E, Shih, AH, Chiu, A, Freinkman, E, Akbay, EA, Steadman, M, Nagaraja, R, Yen, K, Teruya-Feldstein, J, Wong, KK, Rampal, R, Vander Heiden, MG, Thompson, CB & Levine, RL 2018, 'Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)', Journal of Clinical Investigation, vol. 128, no. 10, pp. 4743. https://doi.org/10.1172/JCI124920

@article{4de6281243754065b8ccc9cff354910a,

title = "Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)",

abstract = "Craig B. Thompson's conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below. CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.",

author = "McKenney, {Anna Sophia} and Lau, {Allison N.} and Somasundara, {Amritha Varshini Hanasoge} and Barbara Spitzer and Intlekofer, {Andrew M.} and Jihae Ahn and Kaitlyn Shank and Rapaport, {Franck T.} and Patel, {Minal A.} and Efthymia Papalexi and Shih, {Alan H.} and April Chiu and Elizaveta Freinkman and Akbay, {Esra A.} and Mya Steadman and Raj Nagaraja and Katharine Yen and Julie Teruya-Feldstein and Wong, {Kwok Kin} and Raajit Rampal and {Vander Heiden}, {Matthew G.} and Thompson, {Craig B.} and Levine, {Ross L.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1172/JCI124920",

language = "English (US)",

volume = "128",

pages = "4743",

journal = "Journal of Clinical Investigation",

issn = "0021-9738",

publisher = "The American Society for Clinical Investigation",

number = "10",

}

TY - JOUR

T1 - Corrigendum

T2 - JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)

AU - McKenney, Anna Sophia

AU - Lau, Allison N.

AU - Somasundara, Amritha Varshini Hanasoge

AU - Spitzer, Barbara

AU - Intlekofer, Andrew M.

AU - Ahn, Jihae

AU - Shank, Kaitlyn

AU - Rapaport, Franck T.

AU - Patel, Minal A.

AU - Papalexi, Efthymia

AU - Shih, Alan H.

AU - Chiu, April

AU - Freinkman, Elizaveta

AU - Akbay, Esra A.

AU - Steadman, Mya

AU - Nagaraja, Raj

AU - Yen, Katharine

AU - Teruya-Feldstein, Julie

AU - Wong, Kwok Kin

AU - Rampal, Raajit

AU - Vander Heiden, Matthew G.

AU - Thompson, Craig B.

AU - Levine, Ross L.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Craig B. Thompson's conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below. CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.

AB - Craig B. Thompson's conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below. CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.

UR - http://www.scopus.com/inward/record.url?scp=85054445731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054445731&partnerID=8YFLogxK

U2 - 10.1172/JCI124920

DO - 10.1172/JCI124920

M3 - Comment/debate

C2 - 30222137

AN - SCOPUS:85054445731

SN - 0021-9738

VL - 128

SP - 4743

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

IS - 10

ER -

Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this